Nasus Pharma (NSRX) Stock: Buy, Sell, or Hold?
NSRX - Nasus Pharma Ltd.
$3.49
0.26 (8.05%)
▲
5d:
+9.75%
30d:
+0.29%
90d:
+12.94%
BUY
MODERATE Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Jun 24, 2026
0d
Get Alerted When NSRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: NSRX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: NSRX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: NSRX is currently trading at $3.49, which is considered fair relative to its 30-day fair value range of $3.25 to $3.72.
Technical Outlook: Technically, NSRX is in a uptrend. Immediate support is located at $3.03, while resistance sits at $3.63. The stock is showing strong short-term momentum, up 8.0% recently.
Market Sentiment: NSRX scores 65/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $19.67 (+463.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NSRX is in a uptrend. Immediate support is located at $3.03, while resistance sits at $3.63. The stock is showing strong short-term momentum, up 8.0% recently.
Market Sentiment: NSRX scores 65/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $19.67 (+463.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$3.25 -
$3.72
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
92.1%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (65/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+8.0%)
- BULLISH: Trading 463.5% below Wall St target ($19.67)
- BULLISH: Bottoming setup score 65/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$3.25 -
$3.72
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$3.03
Resistance Level
$3.63
Current Trend
Uptrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.10
Wall Street Target
$19.67
(+463.5%)
Share & Embed Analysis
Last updated: October 25, 2026 10:38 PM ET
Data refreshes hourly during market hours. Next update: 11:38 PM
Data refreshes hourly during market hours. Next update: 11:38 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NSRX showing a specific setup today?
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ABBV
AbbVie Inc |
STRONG BUY
30 analysts |
$285 | 45 HOLD |
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1332 | 33 SELL |
|
MRK
Merck & Company Inc |
STRONG BUY
27 analysts |
$160 | 56 HOLD |
|
GILD
Gilead Sciences Inc |
STRONG BUY
28 analysts |
$160 | 41 HOLD |
|
BIIB
Biogen Inc |
BUY
36 analysts |
$247 | 43 HOLD |